[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsing-polychondritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsing-polychondritis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,77,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100228924","studies-of-the-natural-history-pathogenesis-and-outcome-of-idiopathic-systemic-vasculitis-100228924",false,"NCT02257866","Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis","* INCLUSION CRITERIA:\n\nSUBJECTS WITH VASCULITIS\n\n* Subjects who fulfill modified versions of the 1990 American College of Rheumatology (ACR) Classification Criteria for GPA31 and PAN\n* Subjects who fulfill the 1990 ACR Classification Criteria for EGPA, GCA, and TAK\n* Subjects who fulfill the 2012 Chapel Hill Nomenclature definition for MPA\n* Subjects with other suspected systemic or single-organ vasculitides\n\nHEALTHY VOLUNTEERS\n\n-Volunteers able to provide consent, or in the case of minors, assent\n\nEXCLUSION CRITERIA:\n\nSUBJECTS WITH VASCULITIS:\n\n* Subjects less than 3 years of age\n* Active malignancy, infection, or any medical condition that in the opinion of the investigator would warrant exclusion\n* Inability to provide consent, or in the case of minors, assent\n* Subjects with bleeding diathesis or on anticoagulant medications (e.g. coumadin, heparin, clopidogrel but not including aspirin or NSAIDs) are excluded from participation in nasal brushing or biopsy studies\n\nHEALTHY VOLUNTEERS\n\n* Volunteers less than 3 years of age\n* Diagnosis of vasculitis or other autoimmune\u002Fautoinflamamtory disease, including systemic lupus erythematosus, rheumatoid arthritis, sarcoidosis, mixed connective tissue disease or any overlap autoimmune syndrome\n* Active malignancy, infection, or any medical condition that in the opinion of the investigator would warrant exclusion\n* Pregnant (by history of last menstrual period) or breast feeding subjects\n* Subjects with bleeding diathesis or taking anticoagulant medications (eg coumadin, heparin, clopidogrel but not including aspirin or NSAIDs) are excluded from participating in nasal brushing studies",true,"ALL","3 Years",{"count":19,"type":20},4000,"ESTIMATED","OBSERVATIONAL","Background:\n\n\\- Vasculitis is a group of diseases that inflame and damage blood vessels and tissue. It can cause many medical problems. Few tests can diagnose the disease, and none can reliably predict a relapse. Researchers want to study people s genes and follow people over time to see how the disease affects them.\n\nObjective:\n\n\\- To learn the signs, symptoms, imaging tests, genetic markers, and blood tests that can help identify people with vasculitis and predict what will happen to them over time.\n\nEligibility:\n\n* People age 3 and older who have or are thought to have vasculitis, or are related to someone with it.\n* Healthy volunteers.\n\nDesign:\n\n* Participants will be evaluated by a doctor who has expertise caring for patients with vasculitis.\n* Participants will give a blood sample. Some will give a urine sample.\n* Some participants may have brushings or biopsies taken from the inside lining of the nose.\n* Images of participants blood vessels may be taken using scans. For some scans, participants will lie on a table that moves in and out of a cylinder that takes pictures. For some scans, a contrast agent may be injected into an arm vein. Other scans may use a radioactive form of sugar. Healthy minors will not have scans.\n* Some participants will answer questionnaires. - Some participants will have their tests done at NIH. Others will have their doctor take the blood, saliva, or cheek swab samples and send them to NIH.\n* Some participants will have one visit lasting 1-2 (but sometimes up to 4) days. Some participants may have follow-up visits every 3 - 6 months, indefinitely.",[24,25,26,27,28],"Takayasu's Arteritis","Giant Cell Arteritis","Polyarteritis Nodosa","Relapsing Polychondritis","ANCA-Associated Vasculitis",[26,30,31,27,32,33],"Takayasu's Arthritis","Giant Cell Arthritis","Antineutrophil Cytoplasmic Antibodies","Natural History","RECRUITING","2026-06-13",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":38},"2014-09-29",{"date":42,"type":20},"2050-01-01",{"name":44,"class":45},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100588436","phase-2-an-open-label-study-of-effectiveness-of-immunomodulatory-medications-for-patients-with-relapsing-polychondritis-100588436","NCT06941376","An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","PROSECT RP","Inclusion Criteria:\n\nA. ≥18 years of age\n\nB. Must fulfill McAdam's or Damiani's or Michet's Criteria Diagnostic Criteria for Relapsing Polychondritis McAdam's Criteria (1976)\n\n≥ 3 criteria out of 6 of the following:\n\n1. Bilateral auricular chondritis\n2. Non-erosive seronegative polyarthritis\n3. Nasal chondritis\n4. Ocular inflammation\n5. Respiratory tract chondritis\n6. Cochlear and\u002For vestibular dysfunction\n\nDamiani's Criteria (1979)\n\n1. ≥3 of McAdam's Criteria as above\n2. ≥1 of McAdam's Criteria with histological confirmation of chondritis\n3. ≥2 of McAdam's Criteria with positive response to glucocorticoids or dapsone\n\nMichet's Criteria (1986)\n\nPresence of ≥2 of the following criteria:\n\n1. Auricular chondritis\n2. Nasal chondritis\n3. Laryngotracheal chondritis\n\nOr presence of ≥1 of the above criteria and ≥2 of the following criteria\n\n1. Seronegative inflammatory arthritis\n2. Ocular inflammation\n3. Hearing loss\n4. Vestibular dysfunction\n\nC. Mild to moderately active disease within 60 days prior to screening where the symptoms cannot be attributed to any cause other than RP and which, in the investigator's opinion, requires addition\u002F increase in prednisone dose between 20-60 mg\u002F day.\n\nAt the time of enrollment and during the trial, the following symptoms of active disease which will be evaluated:\n\n1. Auricular inflammation: defined as increase\u002F new onset pain\u002F swelling\u002Fredness of external ear(s), ear canal\n2. Nasal inflammation: defined as increase\u002F new onset pain\u002F swelling\u002Fredness of external nose\n3. Ocular inflammation: defined as new onset\u002F worsening unilateral\u002F bilateral episcleritis\u002Fscleritis\u002F uveitis.\n4. Inflammatory arthritis: defined as new onset\u002F worsening morning stiffness≥30 minutes, physician diagnosed tenderness\u002Fswelling in ≥1 joint; new onset\u002F worsening costochondritis.\n5. Mild to moderate airway inflammation: defined as new onset\u002F worsening mild to moderate inflammation of upper airway diagnosed by direct laryngoscopy and attributed to RP; abnormal CT airway\u002F bronchoscopy showing wall thickening of airway (larynx, trachea, bronchi) and absence of severe manifestations such as new onset SGS\u002Ftracheomalacia\u002F bronchomalacia.\n6. Sinonasal disease: defined as new onset\u002F increase in nasal crusting, discharge bleeding\n7. Constitutional symptoms: defined as new onset\u002F worsening fever, unintentional weight loss of ≥ 5% of body weight, night sweats Patients must have at least 1 of the first 5 criteria within the past 60 days prior to the enrollment.\n\nD. Willing and able to comply with treatment and follow-up procedures.\n\nE. Both men and women of childbearing potential must be willing to use an effective means of birth control while receiving treatment throughout the study. Effective contraception methods include abstinence, oral contraceptives (birth control pills), intra-uterine-device, diaphragm, approved hormone injections, condoms, or medical sterilization.\n\nF. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\nA. Severe disease manifestations within the past 28 days, including:\n\n1. Severe airway inflammation with supplemental oxygen requirement, tracheostomy, airway stenting, ventilation. Patients with prior history of severe airway disease, who currently have damage will be eligible if they have mild- moderate active disease within the past 60 days at the time of enrollment.\n2. Central nervous system (CNS) disease (meningitis, encephalitis, optic neuritis) requiring hospitalization\u002F treatment with intravenous methylprednisolone\u002F cyclophosphamide.\n3. Cardiac disease (symptomatic valve dysfunction, heart failure) requiring active treatment for heart failure\u002F hospitalization\u002F consideration for surgery.\n4. Severe ophthalmologic manifestations: severe scleritis, uveitis, retinal vasculitis, optic neuritis which is imminently vision threatening.\n5. Any disease manifestation considered organ\u002F life-threatening felt to require treatment with prednisone\\>60 mg\u002F day or IV methylprednisolone or cyclophosphamide.\n\nB. Patients with current\u002F prior use of methotrexate or azathioprine will be eligible for stage 1 or stage 2 of the study depending on the duration of treatment with the non- biologic DMARD treatment.\n\nC. Patients with exposure to biologic DMARDS will be excluded.\n\nD. Evidence of active infection.\n\nE. Known infection with human immunodeficiency virus (HIV), hepatitis C, or a positive hepatitis B surface antigen.\n\nF. Patients at risk for tuberculosis (TB) defined as follows:\n\n1. Current clinical, radiographic or laboratory evidence of active TB, even if currently being treated. Chest x-rays (posterior\u002Fanterior and lateral) obtained within the 6 months prior to screening and TB testing (IFN gamma release assay or PPD) performed in the past month prior to screening will be accepted; however, a copy of the reports must be placed in the participant binder.\n2. A history of active TB unless there is documentation that the patient had received prior anti-TB treatment that was appropriate in duration and type according to local health authority guidelines.\n3. Patients with a positive TB screening test indicative of latent TB will not be eligible for the study unless they: i. Have no evidence of current TB based on chest x-ray performed during the screening period and by history and physical exam, and ii. They are currently being treated for latent TB or the site has documentation of successful prior treatment of latent TB. Treatment regimens should be dictated by local guidelines as long as the treatment dose and duration meet or exceed local health authority guidelines. Patients with latent TB may be eligible for the trial prior to completion of treatment as long as they have completed at least 4 weeks of treatment and they have no evidence of current TB on chest x-ray at screening.\n\nG. Inability to comply with study guidelines.\n\nH. Cytopenia: platelet count \\\u003C80,000\u002Fmm3, absolute neutrophil count \\\u003C1500\u002Fmm3, hematocrit \\\u003C 20%.\n\nI. Other uncontrolled disease (co-morbidity) that could prevent a subject from fulfilling the study requirements or that would increase the risk of study procedures.\n\nJ. Patients who have a present malignancy or previous malignancy within the last 5 years prior to screening (except documented history of cured non-metastatic squamous or basal cell skin carcinoma or cervical carcinoma in situ). Patients who had a screening procedure that is suspicious for malignancy, and in whom the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory or other diagnostic evaluations.\n\nK. Receipt of an investigational agent or device within 30 days prior to enrollment\n\nL. A live vaccination \\\u003C 4 weeks before enrollment\n\nM. Presence of any of the following diseases:\n\n1. ANCA-associated vasculitis\n2. Polyarteritis nodosa\n3. Giant cell arteritis\n4. Takayasu's arteritis\n5. Cogan's syndrome\n6. Sarcoidosis\n7. Kawasaki disease\n8. Tuberculosis or atypical mycobacterial infections\n9. Deep fungal infections\n10. Lymphoma, lymphomatoid granulomatosis, or other type of malignancy that mimics vasculitis\n11. Cryoglobulinemic vasculitis\n12. Systemic lupus erythematosus\n13. Rheumatoid arthritis\n14. Overlap with other autoimmune diseases\n15. Diagnosis of VEXAS syndrome","18 Years",{"count":57,"type":20},20,"INTERVENTIONAL",[60],"PHASE2","Open label pragmatic two-stage non-randomized trial comparing the effectiveness of five different standard of care treatment options for patients with relapsing polychondritis (RP).",[27],[27,64,65,66],"RP","Vasculitis","Polychondritis, relapsing","2026-02-03",{"date":69,"type":38},"2026-02-04",{"date":71,"type":38},"2025-08-01",{"date":73,"type":20},"2027-12",{"name":75,"class":76},"University of Pennsylvania","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100433085","longitudinal-study-for-relapsing-polychondritis-100433085","NCT04919538","Longitudinal Study for Relapsing Polychondritis","Inclusion Criteria:\n\n* 1\\. Any subject considered to have a diagnosis of relapsing polychondritis according to the investigator.\n\nExclusion Criteria:\n\n* 1\\. Inability to provide consent, or in the case of minors, assent.",{"count":84,"type":20},100,"Relapsing polychondritis (RP) is a rare systemic inflammatory disease characterized by recurrent inflammation of cartilage including ears, nose, tracheobronchial tree, chest wall and joints. Less commonly, it can cause inflammation of eyes, vasculature, nervous system, skin and inner ear. The purpose of this study is to study the pathogenesis of RP.",[27,65],[64],"2026-01-21",{"date":90,"type":38},"2026-01-23",{"date":92,"type":38},"2021-02-26",{"date":94,"type":20},"2030-01",{"name":75,"class":76},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":58,"phases":105,"briefSummary":107,"conditions":108,"keywords":109,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":46},"100583190","phase-1-efficacy-safety-and-immunological-evaluation-of-upadacitinib-for-relapsing-polychondritis-100583190","NCT06873100","Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis","Inclusion Criteria:\n\n* 1.Male or female ≥18 and ≤70 years\n* 2.Meet the revised Michet criteria\n* 3.Patients had an inadequate response to standard treatment for ≥ 4 weeks. The background treatment included corticosteroids (≤0.5 mg\u002F kg), immunosuppressants ( methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil leflunomide, or cyclophosphamide)\n* 4\\. Negative urine pregnancy test\n* 5\\. Written informed consent form\n\nExclusion Criteria:\n\nAny subject who meets any of the following criteria shall be excluded:\n\n* 1.Use rituximab or other monoclonal antibodies within 2 months.\n* 2.1 months after treatment with high dose glucocorticoid (\\> 1 mg\u002Fkg\u002Fd).\n* 3.Serious complications: heart failure (≥ New York Heart Association（NYHA） III grade), renal insufficiency (creatinine clearance rate ≤ 30 ml\u002Fmin), liver function insufficiency (serum alanine transaminase or glutamic-pyruvic transaminaseT \\> 3 times normal upper limit, or total bilirubin \\> normal upper limit)\n* 4.Other serious, progressive or uncontrollable hematological, gastrointestinal, endocrine, lung, heart, nerve, or brain diseases (including demyelination diseases, such as multiple sclerosis).\n* 5.Known allergies, hyperresponsiveness or IL-2 or its excipients are intolerant.\n* 6.Severe infections (including, but not limited to, hepatitis, pneumonia, bacteremia, pyelonephritis, Epstein-Barr virus, tuberculosis infection), hospitalization for infection, or intravenous antibiotics 2 months before the first dose of treatment.\n* 7.Chest imaging showed abnormalities in malignant tumors or current active infections (including tuberculosis) within 3 months before the first use of the study.\n* 8.Infected with HIV (HIV antibody positive serology) or hepatitis C (Hep C antibody positive serology). If seropositive, consult a doctor with expertise in the treatment of HIV or hepatitis C virus infection.\n* 9.There has been any known malignant tumor or history of malignant tumor in the past 5 years (with the exception of non-melanoma skin cancer, non-melanoma skin cancer with no sign of recurrence or surgically cured cervical tumor within 3 months of use of the first study preparation).\n* 10.There are uncontrolled mental or emotional disorders, including a history of drug and alcohol abuse over the past three years, which may hinder the successful completion of the study. 11.Within 3 months before the first injection of the research agent, during the study period or within 4 months after the last injection of the research agent, any live virus or bacterial vaccine is received or expected to be received. Bacillus Calmette-Guerin was vaccinated within 12 months after screening.\n* 11.Pregnant and lactating women (WCBP) are reluctant to use medically approved contraceptives during and 12 months after treatment.\n* 12.Men whose partners have fertility potential but do not want to use appropriate medically approved contraceptives during and within 12 months of treatment.","70 Years",{"count":104,"type":20},30,[106,60],"PHASE1","Relapsing polychondritis (RP) is a rare, systemic autoimmune disorder characterized by episodic inflammation of cartilaginous structures.\n\nThe goal of this clinical trial is to learn if drug Upadacitinib works to treat relapsing polychondritis in adults. It will also learn about the safety of drug Upadacitinib. The main questions it aims to answer are:\n\n* Does drug Upadacitinib reduce the disease activity of relapsing polychondritis?\n* What medical problems do participants have when taking drug Upadacitinib? Researchers will compare drug Upadacitinib to conventional therapies (treatment with corticosteroids combined with immunosuppressants) to see if drug Upadacitinib works to treat relapsing polychondritis.\n\nParticipants will:\n\n* Take drug Upadacitinib or corticosteroids combined with immunosuppressants every day for 24 weeks.\n* Visit the hospital once every month for checkups and tests. This clinical study will explore the efficacy and immunological evaluation of Upadacitinib in the treatment of RP.",[27],[110,111],"Relapsing polychondritis","Upadacitinib","2025-03-06",{"date":114,"type":38},"2025-03-12",{"date":116,"type":38},"2024-11-15",{"date":118,"type":20},"2026-12-31",{"name":120,"class":76},"Peking University People's Hospital"]